Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
Nov 22, 2023
|
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
Nov 16, 2023
|
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 07, 2023
|
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
Oct 17, 2023
|
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
Oct 05, 2023
|
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
Sep 26, 2023
|
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
Sep 11, 2023
|
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
Sep 08, 2023
|
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
Sep 08, 2023
|
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 08, 2023
|
Displaying 1 - 10 of 20
Print Page
Email Alerts
RSS Feeds
Contact IR

Exit

You are leaving Vigil Neuroscience, Inc.’s website. You may return to Vigil Neuroscience, Inc.’s website by using the “Back” button on your Web browser toolbar or closing the window to the third-party website that you have opened. Do you wish to continue?